CRO WuXi PharmaTech (Cayman), an open-access R&D capability and technology platform company with operations in China and the U.S., will open offices in Boston and San Francisco in early 2015.
These new offices will give the company greater access to innovative companies in the world's two leading biotech hubs, both as customers and as investments. In October, WuXi opened an office in Israel to tap into that biotech community. In addition, the company has U.S. facilities in St. Paul, Philadelphia, Atlanta, Plainsboro (NJ), and San Diego.
"Our vision is to enable anyone and any company to discover and develop healthcare products to benefit the world's patients," said Dr. Ge Li, chairman and CEO of WuXi PharmaTech. "These new offices bring our comprehensive platform of integrated R&D services closer to where entrepreneurs are and where cutting-edge science is being done."
As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners shorten the cycle and lower the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.